Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Neurocrine Biosciences Stock Is Soaring Higher Today

What happened

Shares of the mid-cap biotech Neurocrine Biosciences (NASDAQ: NBIX  ) rocketed higher today as a result of the Food and Drug Administration (FDA) approving the company's first drug, Ingrezza, as a treatment for adults with tardive dyskinesia (TD). Tardive dyskinesia is a movement disorder involving the tongue, lips, face, trunk, and extremities in patients treated with anti-psychotic medications for long periods of time. The drugmaker's shares were up by 23% as of 11:45 a.m. EDT on the back of this positive regulatory news. 

Positive trending chart.

Image source: Getty Images.

So what

Ingrezza is the first drug approved in the U.S. for this rare but debilitating movement disorder. So, from a value-creation standpoint, this first-mover advantage may be worth upwards of $1 billion in peak sales, according to some analysts.  

Now what

Neurocrine isn't wasting any time in getting Ingrezza's commercial launch underway. The company plans to have the drug in the distribution channel by next week through a select pharmacy network. And Ingrezza's broader promotion will reportedly start on May 1.

The one potential hiccup in Ingrezza's commercialization, though, may be the entry of Teva Pharmaceutical Industries'  (NYSE: TEVA  ) rival drug, Austedo. Teva's Austedo is currently under priority review with the FDA, with the agency assigning the drug a Prescription Drug User Fee Act target action date of Aug. 30. So, Austedo could be on the market for TD before the end of 2017.

The good news is that the FDA blessed Ingrezza with a fairly clean label, whereas Austedo already carries a black-box warning for depression when used as a treatment for Huntington's chorea. In other words, Ingrezza should ultimately garner both a first-mover and best-in-class advantage over Teva's drug.

10 stocks we like better than Neurocrine Biosciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Neurocrine Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4013863, ~/Articles/ArticleHandler.aspx, 4/29/2017 1:28:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20940.5 -40.8 -0.2%
Change down S&P 500 2384.2 -4.6 -0.2%
Change down NASD 6047.6 -1.3 0.0%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/28/2017 4:00 PM
NBIX $53.40 Down -0.19 -0.35%
Neurocrine Bioscie… CAPS Rating: ****
TEVA $31.58 Down -0.15 -0.47%
Teva Pharmaceutica… CAPS Rating: *****

Article registration testing

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 00186805602157880074967537608579